A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Eli Lilly and Company

Overview

Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Urologic Neoplasms

Interventions

ALIMTADRUG

gemcitabineDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body. * You must have at least one tumor that can be physically measured or scanned by x-ray. * You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago. Exclusion Criteria: * You may not have used an experimental medicine or device within the past month. * Cancer that has spread to your brain. * If you are unwilling or unable to take folic acid or vitamin B12 supplements.